Stock NRIX NURIX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Real-time Estimate Cboe BZX
Other stock markets
 02:10:32 2024-05-15 pm EDT 		5-day change 1st Jan Change
16.24 USD +8.60% Intraday chart for Nurix Therapeutics, Inc. +17.02% +58.53%
May. 14 Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target MT
Apr. 12 Sector Update: Health Care Stocks Steady Pre-Bell Friday MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Sector Update: Health Care
MT
North American Morning Briefing : Big Banks Kick off Earnings Season
DJ
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share
MT
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours
MT
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M
MT
North American Morning Briefing : Traders Await -2-
DJ
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
DJ
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
CI
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate
MT
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
CI
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years
MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
CI
Nurix Therapeutics, Inc. Presents the Discovery and Chemical Structure of First-In-Class CBL-B Inhibitor NX-1607 at the American Chemical Society Meeting
CI
Nurix Therapeutics Says US FDA Lifts Partial Clinical Hold on Phase 1 Trial of NX-2127
MT
Nurix Therapeutics : FDA Lifts Partial Clinical Hold on NX-2127 Study
DJ
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial
CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Posts Q4 Revenue $15.2M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NRIX Stock
  4. News Nurix Therapeutics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW